Director of the Gamaleya Research Center in Russia Alexander Ginstburg said that the center has developed a vaccine that protects against Delta and Omicron variants of COVID-19, RIA Novosti reported on Saturday. The new vaccine is based on the Russian Sputnik V jab and the clinical trials are expected to last six months.
"This vaccine was created on the same platform as Sputnik, it will be called that, only the antigenic composition will change. It’s even wrong to call it a new vaccine because when we inject the influenza vaccine, every year it has a new antigenic composition, but no one calls it new," Ginstburg added.
